Sanofi Ventures co-led replacement therapy developer Glycomine's latest round, which included Novo, Asahi Kasei Pharma Ventures and Chiesi Ventures.
US-based replacement therapy developer Glycomine completed a $68m series B round yesterday co-led by Sanofi Ventures, the corporate venturing arm of pharmaceutical firm Sanofi, and and venture capital firm Abingworth.
Pharmaceutical firms Novo, Asahi Kasei Pharma and Chiesi Group also participated in the round, the last two through subsidiaries Asahi Kasei Pharma Ventures and Chiesi Ventures. They were joined by RiverVest Venture Partners, Remiges Ventures, Mission Bay Capital and Sanderling Ventures.
Glycomine is working on treatments for congenital diseases of…
